Intelligent Bio Solutions Sees 48% Q2 Revenue Growth and 104% Reader Sales Surge
Intelligent Bio Solutions posted fiscal Q2 revenue of $896,774, a 48% increase year-over-year, with reader sales surging 104% to $246,519 and cartridge sales rising 33% to $516,754. A $9.4 million private placement strengthened assets to $12.17 million and gross profit margin climbed to 49%, supporting planned FDA 510(k) submissions and international expansion.
1. Record Q2 and H1 Revenue Growth
In the fiscal second quarter, Intelligent Bio Solutions generated $896,774 in total revenue, up 48% year-over-year, driven by reader sales of $246,519 (up 104%) and cartridge sales of $516,754 (up 33%). For the six months ended December 31, 2025, total revenue reached $2.01 million, a 36% increase, while gross profit margin expanded by 10 percentage points to 49%.
2. $10M Private Placement Strengthens Balance Sheet
The company closed a $10.0 million private placement in early January, with net proceeds of $9.4 million now reflected in current assets of $12.17 million. These funds are earmarked for working capital, general corporate purposes, and to support planned FDA 510(k) submissions.
3. FDA Pathway and Manufacturing Partnership
Intelligent Bio Solutions has initiated additional clinical studies to advance its FDA 510(k) submission and provided an updated regulatory timeline aimed at unlocking the U.S. market. A newly announced manufacturing partnership is expected to drive cost efficiencies, improve unit economics and support sustainable margin expansion.
4. Strategic Alliances and Major Contract Wins
The company formed a strategic alliance with Vlepis Pty Ltd to enter the consumer health monitoring market and broaden revenue channels. It also secured a major contract with a leading industrial service provider, underscoring growing adoption of its non-invasive drug screening solutions in safety-critical sectors.